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The  Department  of  Nuclear  Sciences  and 
Applications  (NA)  of  the  International  Atomic  Energy 
Agency (IAEA) is committed to contribute to sustainable 
development  in  Member  States  through  the  use  of 
nuclear sciences and their applications in several fields, 
including human health. The Division of Human Health 
(NAHU)  executes  its  programme’s  activities  through 
four  sections:  Applied  Radiation  Biology  and 
Radiotherapy  (ARBR),  Nuclear  Medicine  (NM), 
Dosimetry  and  Medical  Radiation  Physics,  and 
Nutritional and Health-Related Environmental Studies. 
The  objective  of  the  IAEA  programme  in  Human 
Health is to enhance the capabilities in Member States to 
address  needs  related  to  the  prevention,  diagnosis  and 
treatment of health problems through the application of 
nuclear techniques. In particular, ARBR deals primarily 
with  the  clinical  (medical)  use  of  radiation  for  the 
treatment of diseases, mostly cancer. The main objective 
is to improve the availability and safe use of effective 
cancer  management  strategies  in  Member  States,  in 
particular by helping establish new treatment centres in 
countries lacking the basic internationally-accepted level 
of treatment and establishing resource-sparing treatment 
protocols, including guidelines for the treatment of the 
most  common  cancers  in  the  limited-resource  setting. 
The section also organises teaching events and training 
courses for radiation oncologists and support staff, and 
develops more effective treatments for different types of 
cancer based on radiobiological principles, and clinical 
and laboratory studies. Finally, the section also organises 
consultant  and  technical  meetings  for  which  it  uses 
experts  from  different  countries  to  discuss  current 
aspects  in  the  field  of  radiation  oncology  and 
radiobiology of particular importance for member states 
and uses these meetings to advise member states of the 
appropriate implementation in daily practice. Using the 
same  means,  the  mission  of  NM  is  to  enhance 
capabilities  of  developing  Member  States  to  address 
important health needs by the use of nuclear medicine 
functional  studies  or  molecular  biology  techniques  in 
several types of disease, including cancer. In this latter 
field,  among  other  activities  NM  supports  the 
implementation  of  PET  programs  in  countries  where 
national  priorities  and  cancer  management  programs 
include that technology. 
Indeed,  its  already  widely  accepted  biomedical 
techniques involving some type of radiation are often the 
sole means of diagnosis and treatment in a large number 
of  health  problems,  or  complement  non-nuclear 
techniques. Radiotherapy, one of the earliest applications 
of  radiation,  remains  a  major  cost-effective  modality 
available for cancer treatment, often in conjunction with 
diagnostic  radiology  and  nuclear  medicine  procedures 
for tumour localisation. 
In  order  to  optimise  diagnostic  and  treatment 
approaches  to  cancer  conditions  using  nuclear 
technology,  NAHU  acts  as  a  multitask  division, 
frequently  identifying  suitable  topics  and  areas  of 
oncology  where  cross-cutting  activities  of  several 
sections are identified and discussed. Some of the most 
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recent  cross-cutting  activities  in  NAHU  included 
consultant meeting in optimisation of palliation of bone 
metastasis  (December  2005),  a  technical  meeting  on 
intensity-modulated  radiation  therapy  (IMRT)  (June, 
2006) and a consultant meeting on nutrition and cancer 
(October 2006). 
In relation to cancer management, one of the fastest 
growing techniques in developed countries is PET with 
increasing  involvement  of  nuclear  medicine  in  the 
domain  of  oncology,  including  radiation  oncology. 
Functional imaging by means of PET has facilitated the 
evaluation  of  tumour  physiology,  metabolism  and 
proliferation,  which  are  parameters  relevant  to  the 
outcome  following  treatment.  It  has  been  proved  that 
compared  with  CT,  PET  has  higher  sensitivity  and 
specificity  for  staging  many  types  of  cancer,  higher 
sensitivity and specificity for imaging their recurrences, 
and higher sensitivity and specificity for monitoring the 
effects of therapy. 
For radiotherapy planning (RTP), CT represents the 
current  gold  standard.  However,  the  development  of 
biologic imaging by PET brings new information about 
cancer.  The  modern  images  integrate  many  biologic 
aspects,  including  data  on  genotypic  and  phenotypic 
expression,  metabolic  activity,  and  cell  proliferation. 
These  elements  are  very  useful  to  draw  more  specific 
strategies for treating cancer. Nuclear medicine with PET 
offers  significant  contributions  in  defining  the  volume 
for  treatment.  This  imaging  is  based  on  different 
radiopharmaceuticals,  and  is  able  to  describe  glucose 
metabolism,  cell  proliferation,  angiogenesis,  and/or 
hypoxia.  The  nuclear  medicine  images  can  be  co-
registered  and  fused  with  CT  and  also  MRI,  and  give 
both morphological and functional information that are 
incorporated into RTP for a better definition of the target 
volumes. 
The  integration  of  nuclear  medicine  imaging  into 
RTP leads to a definition of a new concept of target, the 
biological  target  volume  (BTV).  According  to  the 
radiopharmaceutical  used,  the  BTV  expresses  different 
properties  of  the  tumour.  The  term  of  ‘theragnostic 
imaging’ as the multimodality imaging can be kept as a 
guide for designing the highest dose spots in the context 
of the tumour. The difference between this concept and 
the morphological imaging is that it provides information 
to determine how and not only where radiation therapy 
should be delivered. The attention should also be focused 
on the functional aspects and the importance of healthy 
tissues so as to reduce the radio-induced damage. 
The inclusion of flourodeoxyglucose (FDG)-PET in 
the  RTP  has  as  first  goal,  the  improvement  of  cancer 
staging  and  the  identification  of  the  tumour  volume, 
using the anatomic imaging as a frame for the calculation 
of  the  dose.  This  may  have  significant  effects.  The 
impact of PET on the target delineation is related to the 
accuracy  of  the  study  (diagnostic  sensitivity  and 
specificity)  for  the  type  of  cancer  to  be  treated.  PET 
affects the treatment planning according to the requests 
from the radiation oncologists. 
Besides the added value in defining planning target 
volume (PTV), the most promising use of multimodality 
imaging  is  the  characterisation  of  biochemical  and 
physiological features of the tumour, and this can guide 
the delineation of tumour sub-volumes to be boosted. 
A  further  possibility  offered  by  the  metabolic 
imaging  is  the  prediction  of  the  responsiveness  to 
radiotherapy  during  the  early  phase  of  treatment. 
Monitoring the reduction of FDG uptake (through SUV 
changes)  in  a  semi-quantitative  way,  can  allow  the 
optimisation of the treatment and modify the strategy of 
the  original  plan.  Another  role  of  nuclear  medicine  in 
RTP  is  the  definition  of  healthy  tissues  to  be  spared, 
instead of the tumour volumes delineation. Imaging can 
allow the identification of non-functional tissues and thus 
guide the beam set-up. 
The use of multimodal imaging in the RTP requires 
several  steps.  First  of  all,  the  image  fusion  that  is  the 
transfer of information from one study to another. The 
second step is the image co-registration, which gives a 
spatial  mapping  of  the  corresponding  points  of  the 
images. The third step is the delineation of the volume 
based on a metabolic radiopharmaceutical uptake. 
Different  positron-emitting  radionuclides  must  be 
used  and  their  pharmacokinetics  optimised  before 
implementing  PET  in  routine  clinical  practice  for  the 
purpose  of  changing  radiotherapy  (RT)  volumes  and 
predicting response to RT. Moreover, attention needs to 
be focused on patient motion, partial volume effects and 
image  resolution,  in  order  to  decrease  artefacts  and 
improve  image  quality.  Therefore,  it  should  be 
understood  that  the  use  of  PET  for  target  volumes 
delineation  requires  specific  parameters  for  image 
acquisition  and  processing,  and  these  parameters  may 
differ  according  to  the  different  tumour  types.  For 
instance,  there  are  several  ways  to  assess  tumour 
viability by quantifying tracer uptake in the tumour and 
to project this information onto the anatomical transaxial 
CT images. In fact, although the nuclear physician makes 
the  analysis  mostly  with  a  qualitative  approach,  the 
radiation oncologist needs a quantitative evaluation. This 
is an emerging field, but to date robust clinical data are 
still needed. 
Specialists in radiation oncology, nuclear medicine, 
diagnostic radiology and medical physicists are involved 
in  this  work,  where  appropriate  team  coordination  is 
crucial for effective application of the technology. One 
of IAEA’s projects is to work on the standardisation of 
PET/CT protocols across the different centres throughout 
the world. 
A  consultant  meeting  was  held  in  Vienna  in  July 
2006 to advise the IAEA on the current state of the art 
use  of  PET/CT  in  the  treatment  planning  of  the  most 
common solid tumours, with special emphasis on lung 
cancer.  This  consultant  meeting  was  the  basis  for 
discussions and advice to the IAEA on the suitability of 
having  a  Coordinated  Research  Project  (CRP),  which 
will include participation of scientific investigators from 
Member  States,  and  also  to  discuss  and  draft  a 
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During the consultant meeting, participants presented the 
institutional  experience  in  this  field.  The  relevant 
literature was reviewed and the areas of major interest 
and research identified. Also, the implementation of this 
technology in developing countries had been thoroughly 
discussed  from  both  clinical  research  and  cost-
effectiveness standpoints. Topics for CRPs in developing 
countries were identified. This activity may have special 
interest  for  centres  starting  to  use  PET/CT  in  RTP  in 
developing countries. 
It  was  unequivocally  agreed  that  IAEA  should 
further  assess  and  eventually  promote  the  usage  of 
PET/CT  in  RTP.  Standardisation  of  the  techniques  to 
delineate  target  volumes  with  PET/CT  was  seen  as 
essential and this issue needs to be developed. Clinical 
outcome after implementation of such a technique in RT 
should be assessed in different tumour types in order to 
justify  its  use.  Conducting  multicentric  cooperative 
international  studies  should  be  promoted  to  help 
accomplish these objectives in the near future. 
Major recommendations from this meeting were that 
IAEA  should  consider  providing  more  developing 
countries  with  three-dimensional  conformal  radiation 
therapy (3D-CRT) technology to make them adequately 
equipped for the introduction of PET-CT in the treatment 
planning  process.  An  increasing  knowledge-transfer  of 
PET-CT  technology  to  developing  countries  should  be 
sought,  providing  appropriate  nuclear  medicine 
infrastructure and adequate human resources where this 
is available. Research efforts on the integration of PET 
imaging  into  RTP  should  be  encouraged,  providing 
appropriate 3D-CRT infrastructure and adequate human 
resources.  To  obtain  sustainable  quality  in  this  novel 
approach,  standardisation  of  PET  and  PET/CT 
acquisition  protocols  for  both  staging  and  treatment 
planning,  and  also  PET/CT-based  target  volume 
delineation for RTP should be encouraged. 
Using  IAEA-funded  CRP  framework,  timely 
activities  should  be  concentrated  on  the  evaluation  of 
outcome  of  PET-based  RTP,  more  likely  in  non-small 
cell  lung  cancer  due  to  the  overall  burden  of  these 
tumours  worldwide.  Last,  but  not  least,  IAEA  should 
encourage  the  clinical  evaluation  of  new 
radiopharmaceuticals  to  aid  in  the  delineation  and  the 
biological characterisation of the gross tumour volume. 
It was proposed that IAEA consider the following 
ideas as suitable for potential CRPs: standardisation of 
delineation of target volumes using PET-based treatment 
planning;  evaluation  of  local  failure  after  either  CT-
based or PET-based radiation therapy; changes in PET 
scans after radiation therapy as a predictor of response 
and determination of salvage treatment. 
The consultant meeting was proven to be a fruitful 
event  enabling  IAEA/NAHU  to  continue  monitoring 
current achievements in this field and to put emphasis on 
research studies aimed at evaluating the use of PET-CT 
in RTP, a task to be defined during a planned meeting in 
2007. To further strengthen its interest in the application 
of this technology in monitoring the treatment response 
in  cancer  patients,  ARBR  and  NM  are  planning  to 
organise another consultant meeting in 2007 as one of 
the  possible  activities  that  may  request  timely  IAEA-
funded research in this field. 